- Home
- FTHM vs CGTX Comparison
FTHM vs CGTX Comparison
Compare FTHM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- CGTX
- Stock Information
- Founded
- FTHM 2010
- CGTX 2007
- Country
- FTHM United States
- CGTX United States
- Employees
- FTHM N/A
- CGTX N/A
- Industry
- FTHM Real Estate
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- CGTX Health Care
- Exchange
- FTHM Nasdaq
- CGTX Nasdaq
- Market Cap
- FTHM 33.6M
- CGTX 25.1M
- IPO Year
- FTHM 2020
- CGTX 2021
- Fundamental
- Price
- FTHM $1.26
- CGTX $0.57
- Analyst Decision
- FTHM Buy
- CGTX Strong Buy
- Analyst Count
- FTHM 1
- CGTX 4
- Target Price
- FTHM $2.50
- CGTX $2.83
- AVG Volume (30 Days)
- FTHM 88.3K
- CGTX 17.4M
- Earning Date
- FTHM 08-11-2025
- CGTX 08-07-2025
- Dividend Yield
- FTHM N/A
- CGTX N/A
- EPS Growth
- FTHM N/A
- CGTX N/A
- EPS
- FTHM N/A
- CGTX N/A
- Revenue
- FTHM $357,816,000.00
- CGTX N/A
- Revenue This Year
- FTHM $32.40
- CGTX N/A
- Revenue Next Year
- FTHM $18.04
- CGTX N/A
- P/E Ratio
- FTHM N/A
- CGTX N/A
- Revenue Growth
- FTHM 5.80
- CGTX N/A
- 52 Week Low
- FTHM $0.65
- CGTX $0.22
- 52 Week High
- FTHM $3.37
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- FTHM 51.56
- CGTX 61.68
- Support Level
- FTHM $1.27
- CGTX $0.56
- Resistance Level
- FTHM $1.36
- CGTX $1.04
- Average True Range (ATR)
- FTHM 0.11
- CGTX 0.09
- MACD
- FTHM -0.01
- CGTX 0.03
- Stochastic Oscillator
- FTHM 53.12
- CGTX 36.81
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.